8-K: Oruka Therapeutics Completes Merger with ARCA biopharma, Secures $275 Million in Private Placement

Oruka Therapeutics has finalized its merger with ARCA biopharma, raising $275 million in a private placement and appointing a new board chairman, with shares now trading on Nasdaq under the symbol ORKA.

Summary

• Oruka Therapeutics, Inc. has completed its merger with ARCA biopharma, Inc., and the combined company will now operate under the name Oruka Therapeutics, Inc.
• The company's shares began trading on the Nasdaq Global Market on September 3, 2024, under the ticker symbol ORKA.
• Oruka also completed a $275 million private placement with new and existing investors.
• Following the merger, private placement, and a 1-for-12 reverse stock split, there are approximately 46.3 million shares of the combined company's common stock and common stock equivalents outstanding.
• The company is focused on developing novel biologics for chronic skin diseases, with lead programs ORKA-001 and ORKA-002 expected to enter clinical trials soon.
• ORKA-001 is a monoclonal antibody targeting IL-23p19, designed for less frequent dosing and higher efficacy than current treatments.
• ORKA-002 is a monoclonal antibody targeting IL-17A/F, designed for less frequent dosing and similar efficacy to current treatments for psoriasis and psoriatic arthritis.
• Oruka paid a special cash dividend of approximately $23.4 million, or $1.613 per share, to ARCA stockholders of record as of August 26, 2024.

Sentiment

Score: 8

Explanation: The document is generally positive, highlighting the successful merger, significant funding, and promising pipeline. The management comments are optimistic, and the company is well-positioned for future growth. However, the document also acknowledges the risks associated with early-stage biotech companies.

Positives

• The merger provides Oruka with access to public markets and additional capital.
• The $275 million private placement provides significant funding for Orukas development programs.
• The appointment of Samarth Kulkarni as Chairman adds significant industry expertise to the board.
• Orukas lead programs, ORKA-001 and ORKA-002, have the potential to be best-in-class treatments for psoriasis and related conditions.
• The company has a clear strategy focused on I&I diseases, specifically inflammatory dermatology conditions.

Negatives

• The document does not explicitly state any negatives.

Risks

• The company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry.
• The company will need substantial additional funding to support its operating activities.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company may not be able to generate revenue from product sales.
• The company may not be able to achieve or maintain profitability.
• The company is subject to risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, rising interest rates, recent bank failures, geopolitical factors, and supply chain disruptions.

Future Outlook

Oruka expects to incur significant expenses and operating losses for the foreseeable future as it continues to develop its programs and operate as a public company. Oruka believes that its existing cash, together with the proceeds from the Merger and Orukas Pre-closing financing, will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of the financial statements.

Management Comments

• We have made tremendous progress since our founding in February of this year. We have assembled a top-tier team that has executed effectively to both close this transaction and advance our co-lead programs toward human trials, said Lawrence Klein, PhD, Chief Executive Officer of Oruka.
• Our drug candidates are designed to potentially offer both improved dosing regimens and greater clinical activity compared to the current standard of care for patients with psoriasis and related conditions.
• Orukas product candidates have incredible potential to change the landscape of treatment for multiple diseases, commented Samarth Kulkarni, PhD.
• I am very impressed with the work the team has completed to date and believe they are well positioned to deliver on the immense promise of their programs moving forward.

Industry Context

The announcement highlights the ongoing trend of mergers and acquisitions in the biotechnology sector, particularly in the area of inflammatory and immunology diseases. The focus on novel biologics and improved dosing regimens reflects the industry's push for more effective and convenient treatments.

Comparison to Industry Standards

• Orukas lead programs, ORKA-001 and ORKA-002, are designed to target mechanisms with proven efficacy and safety, similar to other successful treatments for psoriasis and psoriatic arthritis, such as AbbVie's Skyrizi (risankizumab) and Eli Lilly's Taltz (ixekizumab).
• The company's focus on half-life extension technology is consistent with the industry's trend towards developing less frequent dosing regimens, which is a key differentiator for products like Johnson & Johnson's Tremfya (guselkumab) and UCB's Bimzelx (bimekizumab).
• Orukas goal of achieving higher rates of disease clearance with ORKA-001 is similar to the clinical trial results of bimekizumab, which has shown high PASI 100 rates in psoriasis patients.
• The company's focus on dual inhibition of IL-17A and F with ORKA-002 is similar to the approach taken by UCB with bimekizumab, which has shown promising efficacy in psoriasis and psoriatic arthritis.

Management Changes

Corporate Governance

Legal Proceedings

• The document incorporates by reference information about legal proceedings from the Proxy Statement/Prospectus, but does not detail any new legal proceedings.

Related Party Transactions

• The document mentions that the Company issued 20,000,000 shares of Series A convertible preferred stock to Fairmount Healthcare Fund II, L.P. at a purchase price of $0.15 per share for gross proceeds of $3.0 million.
• The document mentions that the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement with Fairmount Healthcare Fund II, L.P., whereby the Company issued a convertible note, with an initial principal amount of $25.0 million.
• The document mentions that the Company entered into the Paragon Option Agreements with Paragon and Paruka, which are related parties.

Stakeholder Impact

• Shareholders of ARCA received a special cash dividend of $1.613 per share.
• Shareholders of ARCA and Oruka were diluted as a result of the merger and private placement.
• Employees of Oruka will benefit from the increased resources and opportunities provided by the merger and private placement.
• Customers and patients may benefit from the development of new and improved treatments for chronic skin diseases.
• Suppliers and vendors may benefit from increased business opportunities with the combined company.

Next Steps

• Oruka plans to initiate a Phase 1 trial of ORKA-001 in the first half of 2025.
• Oruka plans to initiate Phase 1 trials of ORKA-002 in the second half of 2025.

Key Dates

Keywords

Oruka Therapeutics, ARCA biopharma, merger, private placement, biologics, psoriasis, IL-23p19, IL-17A/F, monoclonal antibody, clinical trials, Nasdaq, ORKA-001, ORKA-002